Merck & Co.
Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases.
Pfizer Canada strives to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines. Our diverse portfolio offers a broad range of benefits and solutions to meet the needs of Canadians.
Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
The Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is approved for people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months has not yet been established.
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose ...
Our Products. Our diversified health care portfolio includes some of the world’s best-known prescription medicines and vaccines. If you encounter difficulties in viewing our product information please refer to the Health Canada Drug Product Database site.
pfizer-biontech covid-19 vaccine (covid-19 mrna vaccine) On September 16, 2021, Health Canada granted full approval (Notice of Compliance or NOC) for COMIRNATY™. The vaccine was initially authorized for use in Canada under an Interim Order Authorization on December 9, 2020 under the name Pfizer-BioNTech COVID-19 Vaccine.
